Clinical Trial Update: A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

A prospective, single-center Phase 2 study assessing the efficacy and safety of combining Glofitamab with Orelabrutinib and Bortezomib in high-risk mantle cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• Glofitamab (glofitamab)
• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: Ruijin Hospital | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING